• Arbutus completed a modified Dutch auction tender offer, repurchasing 46,000,000 common shares for cancellation at US$ 5.00 each.
• Total buyback value reached US$ 230 million, representing about 23% of shares outstanding as of Sept. 29, 2026.
• Offer was oversubscribed; eligible tenders at or below US$ 5.00 were prorated to about 55.6%, excluding odd lots.
• Roivant Sciences tendered in the proportionate pool, maintaining about 19.5% ownership following completion.
• Shares not purchased will be returned; payment and settlement expected around Oct. 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010730PRIMZONEFULLFEED9837627) on October 01, 2026, and is solely responsible for the information contained therein.